Undiagnosed, untreated blood disorders in women and young girls have medical consequences and unique issues at every life stage, creating the need for a foundation dedicated to education and awareness.
We work to achieve this goal by raising awareness and educating the key healthcare providers for each particular life stage and translating and disseminating provider information and research.
In our next Case Conversation program on Tuesday, May 24th, from 12:00-1:00 p.m. ET (11:00 a.m. - 12:00 p.m. CT, 10:00 - 11:00 a.m. MT, 9:00-10:00 a.m. PT), where Dr. Michele Lambert…
Join FWGBD at its second biennial educational conference for professionals dedicated to the care and support of women and girls with blood disorders. The FWGBD 2022 Conference will be held on&…
The Foundation for Women & Girls with Blood Disorders Research Awards provide financial support for qualified fellows or junior attending/junior faculty pursuing clinical, t…
Join both Dr. Lakshmi Srivaths and Dr. Bethany Samuelson Bannow for their upcoming Webinar: Throboembolism in Females. During the live program, they discuss the following: Thromboembolism…
Dr. Leslie Appiah of the University of Colorado will be presenting at NASPAG's upcoming Fertility Preservation: Optimizing Outcomes webinar on January 13 from 8-9 pm ET.
Our congratulations to Dr. Roshni Kulkarni, FWGBD Co-Founder and Board Member, for her selection as the 2022 Coalition for Hemophilia B's Eternal Spirit Award.
MAC Member Dr. Michael Paidas has co-developed a novel therapeutic that acts as a "net" to prevent COVID-19 from entering cells.
Dr. Andrew is researching clinical trial design for postpartum women with risk of venous thromboembolism (VTE).
NASPAG has created a set of talking points to help health care providers answer questions from parents and adolescents about the safety and efficacy of the Pfizer-BioNtech vaccine.
The CDC has recently released updated statistics about hemophilia characteristics among women and girls receiving care at specialized Hemophilia Treatment Centers (HTCs) in the United States.
